Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.

Front Immunol · 2021 · PMC8137893 · PMID 34025662

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Of note, in the phase II trial, KEYNOTE-022, dual dabrafenib/trametinib plus pembrolizumab showed a numerical increase in PFS compared to dabrafenib/trametinib plus placebo (16 vs.10.3 months); however, this did not reach statistical significance ( 135 , 136 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.